NDPS Act Compliance for Pharma: Key Updates in 2025–26

India’s NDPS Compliance Landscape: What Changed Between December 2025 and April 2026

Three overlapping developments have landed squarely on the compliance desks of India’s pharmaceutical manufacturers in the past five months: a formal gazette amendment to import and export procedures, a restructured CBN Registration Certificate regime, and a surge in multi-state enforcement actions accompanied by sharpened High Court scrutiny. Taken together, these changes raise the compliance bar considerably — and the window for course-correction is narrowing.

1. NDPS (Amendment) Rules, 2025 — New Import and Export Obligations

The most consequential recent change is the Narcotic Drugs and Psychotropic Substances (Amendment) Rules, 2025, notified by the Ministry of Finance on 10 December 2025 under Sections 4, 9, and 76 of the NDPS Act, 1985. The amendment revises two cornerstone documents in narcotic trade:

• Form 4A — Import Certificate for import of narcotic drugs under Rule 54
• Form 5 — Export Authorisation for export of narcotic drugs and psychotropic substances

What the Revised Form 4A Requires

The overhauled Form 4A now demands a higher level of documentation granularity from importers. Specifically, companies must supply the HSN Code, CAS number, and their GSTIN as mandatory fields. Critically, importers must complete all imports within 180 days of certificate issuance, with strict adherence to security, accounting, and reporting procedures throughout that window. Analytical imports are restricted exclusively to laboratory use, and any unused substances must be surrendered to Government Opium and Alkaloids Works (GOAW).

What the Revised Form 5 Requires

For exporters, the revised Form 5 expands documentation obligations significantly. Exporters must now submit shipping bills and invoices directly to both the Narcotics Commissioner and the Drugs Controller General of India (DCGI). For manufacturers producing formulations intended for export using imported morphine, codeine, thebaine, or their salts, diversion to domestic markets is expressly prohibited.

The overarching intent of these amendments is to strengthen traceability and align India’s framework with international narcotics control standards — consistent with India’s obligations under the Single Convention on Narcotic Drugs, 1961, and the Convention on Psychotropic Substances, 1971.

Practical Action Points

1. Audit all existing import certificates — check whether the 180-day completion window is being tracked.
2. Update internal SOPs to incorporate new Form 4A fields (HSN Code, CAS number, GSTIN) before the next import application cycle.
3. Establish a documented dual-submission workflow for Form 5 exports (to both CBN and DCGI).
4. Ensure analytical import records clearly segregate laboratory-use quantities from commercial stock.

2. CBN Registration Certificates — Physical Issuance Under Rule 65 Now Formalised

In a parallel development, the Central Bureau of Narcotics (CBN) has begun issuing CBN Registration Certificates (CRCs) in physical form under Rule 65 of the NDPS Rules, 1985. This follows recognition by the CBN that the absence of a formal, tangible certificate had been creating operational difficulties for registered companies — particularly during regulatory inspections and international trade documentation checks.

All manufacturers of psychotropic substances are required to register with the Narcotics Commissioner and are allotted a permanent registration number. The newly issued physical CRCs now incorporate enhanced security features to prevent forgery and misuse.

Applications for CRCs can be submitted via email or other prescribed means. The CBN has specifically noted that companies must ensure full accuracy of details and supporting documents to avoid processing delays. Additionally, the CBN’s online portal at cbnonline.gov.in continues to be the primary channel for return filings — manufacturers and dealers of narcotic drugs, and manufacturers and traders of psychotropic substances, are required to file monthly returns on this platform, with submissions due on or before the 7th day of the following month.

Practical Action Points

1. If your company manufactures psychotropic substances and does not yet hold a physical CRC, initiate the application process with the Narcotics Commissioner immediately.
2. Verify that your permanent CBN registration number is correctly reflected across all trade documents, manufacturing licences, and import/export applications.
3. Confirm that monthly returns are being filed on cbnonline.gov.in by the 7th of each month — failure to file can result in non-issuance of future export authorisations.

3. Annual Quota Applications for 2026 — Act Before Allocations Close

The CBN has issued public notices for online quota applications for narcotic drugs for the year 2026, as well as for the provisional quota allocation of psychotropic substances for calendar year 2026. Quota allocations, approved in line with INCB (International Narcotics Control Board) estimates, are a hard ceiling on what a manufacturer can legally procure and produce.

The CBN has also issued a separate public notice regarding the requirement of Export/Import Certificates specifically for codeine preparations — a category that, as the judicial developments below underscore, is under heightened regulatory and enforcement scrutiny.

Companies that miss quota application windows face significant production disruptions. API and bulk drug manufacturers who did not secure psychotropic substance quotas for 2025 should treat the 2026 allocation cycle as a priority compliance task.

4. Enforcement Surge and Judicial Developments — The Compliance Stakes Are Higher Than Ever

Multi-State Crackdowns on Codeine and Narcotic Drug Diversion (April 2026)

As reported on 13 April 2026, pharmaceutical drug diversion — particularly of codeine-based cough syrups and narcotic tablets including Tramadol, Nitrazepam, and Tapentadol — has surged nationwide, with enforcement agencies conducting coordinated multi-state raids. The pattern of seizures exposes systemic weaknesses in supply chain documentation and distributor oversight at the manufacturer level.

Critically, a Drug Diversion Control (DCC) portal proposal that could help regulators track such diversions in real time has faced implementation delays, leaving the burden of diversion prevention squarely on manufacturers’ internal compliance systems in the interim.

Patna High Court — April 2026: NDPS Misapplication in Codeine Syrup Cases

On 4 April 2026, the Patna High Court (Justice Ashok Kumar Pandey, in Sanjeev Kumar vs State of Bihar) observed that police authorities are “invariably misusing” NDPS Act provisions in cases involving cough syrups containing permissible levels of codeine, holding that such matters ought properly to be addressed under the Drugs and Cosmetics Act rather than the more stringent NDPS regime.

However, this observation must be read in context. Courts have also consistently held the converse: where codeine-based preparations are possessed or transported without authorisation — regardless of whether the concentration is below 2.5% — the NDPS Act applies fully, and bail under Section 37 becomes extremely difficult to obtain. The Patna High Court itself, in an earlier ruling dated 27 August 2025, denied bail to an accused found transporting 40 bottles of codeine syrup across the Indo-Nepal border, applying the Hira Singh mixture rule to treat the entire 4-litre quantity as the relevant commercial quantity.

The legal landscape therefore creates a precise compliance imperative: being a licensed pharmaceutical company is necessary, but not sufficient. The regulatory pathway — valid licences, accurate documentation, authorised channels of distribution — must be demonstrably intact at every stage.

Key Legal Principle Every Pharma Company Must Internalise

Section 80 of the NDPS Act expressly provides that its provisions shall be in addition to, and not in derogation of, the Drugs and Cosmetics Act. This means that a company facing a compliance failure can simultaneously be exposed to penalties under both statutes. The Drugs and Cosmetics Act is not a safe harbour from NDPS prosecution where narcotic or psychotropic substances are involved.

5. Controlled Substances Amendment Order, 2025

Separately, the Government notified the Narcotic Drugs and Psychotropic Substances (Regulation of Controlled Substances) Amendment Order, 2025, amending Schedule B and Schedule C of the principal NDPS (Regulation of Controlled Substances) Order, 2013 (originally notified as G.S.R. 191(E) dated 26 March 2013). The amendment inserts new serial numbers and entries under both schedules. Companies dealing in precursor chemicals and controlled substances must review their product portfolios against the updated schedules to confirm whether any existing ingredients or intermediates now fall under additional control categories.

Summary: What Pharmaceutical Companies Must Do Now

• Update import/export documentation to reflect the revised Form 4A and Form 5 requirements under the NDPS (Amendment) Rules, 2025 (10 December 2025).
• Track the 180-day import completion deadline for all active certificates.
• Apply for your 2026 narcotic drug and psychotropic substance quotas via cbnonline.gov.in without delay.
• Obtain your physical CBN Registration Certificate (CRC) under Rule 65, ensuring all submitted details are accurate.
• File monthly returns by the 7th of each month — non-compliance directly jeopardises future export authorisations.
• Review your portfolio against the updated Schedules B and C under the Controlled Substances Amendment Order, 2025.
• Audit your distribution chain for codeine preparations and Schedule H1/X drugs, ensuring complete documentation at each handoff point.
• Train your compliance team on the dual-applicability of the NDPS Act and the Drugs and Cosmetics Act — regulatory classification does not insulate a company from NDPS exposure.

ACPL’s regulatory experts can help you navigate NDPS Act and narcotics compliance for your pharmaceutical business. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.